SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes

This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with type 2 diabetes.

from JAMA Internal Medicine Online First https://ift.tt/Qt6whNW